C
hagas disease (CD) is caused by the obligate intracellular protozoan Trypanosoma cruzi. More than a hundred years after its discovery (1), CD is still an important public health problem, and about 6 million to 7 million people, mostly in Latin America, are estimated to be infected worldwide (2) . Of these infected individuals, 30 to 40% develop cardiomyopathy and/or digestive syndromes (3) . For over 4 decades, nifurtimox [3-methyl-4 -(5=-nitrofurfurylideneamine tetrahydro-4H-1,4-tiazine-1,1-dioxide)] and benznidazole (Bz; N-benzyl-2-nitroimidazole acetamide), which have been used as empirical therapy for CD, have remained the sole treatment options (4) . Both have several limitations, including a variety of adverse effects and limited efficacy in the later chronic phase of infection (5, 6) , characteristics which strengthen the need for new trypanocidal compounds that overcome these limitations.
Classic aromatic diamidines (ADs) are DNA minor groove binders with recognized broad-spectrum antimicrobial and antitumor activities (7) . ADs, such as pentamidine, diminazene, and propamidine, have been used as therapies in human and veterinary medicine for decades, but despite their excellent antiparasitic effects, they have relevant drawbacks that include low bioavailability and side effects. To overcome these limitations, new analogues have been synthesized and tested in vivo and in vitro (7) . Several ADs and related compounds have been screened for their activities against T. cruzi and have shown promising results, at least in part due to their capacity to alter the kinetoplast DNA molecule (8, 9) . Arylimidamides (AIAs; formerly called "reversed" amidines, because of the reversed position of the nitrogen and carbon atoms compared to their orientation in classic aromatic amidines) are the most effective amidine analogues tested against T. cruzi in vitro and in vivo (9) (10) (11) (12) .
Lipid bodies (LBs) consist of a nucleus of cholesteryl esters and triglycerides surrounded by a single monolayer of phospholipids. LBs are considered not only lipid storage compartments but also intracellular sites for many biological events, like cellular signaling and activation, regulation of lipid metabolism, membrane trafficking, and regulation of inflammatory mediators (13, 14) . Recent studies proposed a dynamic role of LBs in the control of pathogen infections due to their localization inside the parasitophorous vacuoles in intracellular parasites like T. cruzi (15) .
Our present study focused on an analysis of the activities of 12 novel bis-AIAs and 2 mono-AIAs against bloodstream trypomastigotes (BTs) and intracellular forms of T. cruzi (the Tulahuen, Y, and Colombiana strains) in vitro. The most potent and most se-lective compound tested, 35DAP073, underwent further screening in experimental mouse models of acute parasite infection (with strains Y and Colombiana) alone or combined with the reference drug (Bz) with the aim of contributing to the search for novel alternative protocols for the treatment of CD.
MATERIALS AND METHODS
Synthesis of the arylimidamides. The synthesis of the four m-terphenyl bisarylimidamides 35DAP069, 35DAP073, 35DAP077, and 35DAP081 and the two monoarylimidamides 35DAP092 and 38DAP096 ( Fig. 1 ) has been described previously (16) , wherein the final step was the reaction of the appropriate terphenyl amine or diamine with benzonitrile or 2-cyanopyridine using sodium bis(trimethylsilyl)amide in tetrahydrofuran. Similar reactions involving 1,4-diphenylenediamine and 2,5-or 2,6-diaminopyridine were employed for the synthesis of 19SAB003, 19SAB005, 19SAB007, and 28SMB008 (17) (Fig. 2) . Compounds 23SMB046, 23SMB050, 26SMB060, and 27SMB005 (Fig. 3) were prepared by a previously described methodology from the methyl imidate derivatives of 2-or 4-cyanopyridine and the appropriate ␣,-diaminoalkane (18). All 14 compounds were isolated as their hydrochloride salts. Experimental details and physical data for the compounds shown in Fig. 2 and 3 are given in Text S1 in the supplemental material.
Stock solutions of the tested compounds. The studied molecules were prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich), with the final concentration of the solvent (obtained by dilution using RPMI 1640 medium) never exceeding 0.6% and 10% for the in vitro and in vivo analyses, respectively. The solvent did not exert toxicity on parasites or mammalian host cells (data not shown). Bz was purchased from the Laboratório Farmacêutico do Estado de Pernambuco (LAFEPE), Brazil. Bz was dissolved in distilled and sterile water supplemented with 3% Tween 80 and does not have any detectable effect on mice (19) .
Mammalian cell cultures. Primary cultures of embryonic cardiac cells (CCs) were obtained from Swiss Webster mice as previously reported (20) . After purification, the CCs were seeded into 24-and 96-well microplates containing gelatin-coated coverslips at densities of 0.2 ϫ 10 6 and 0.05 ϫ 10 6 cells/well, respectively, as reported previously (18) . The cardiac cell cultures were then sustained at 37°C in Dulbecco's modified Eagle medium (DMEM; without phenol red; Sigma-Aldrich) supplemented with 10% horse serum, 5% fetal bovine serum, 2.5 mM CaCl 2 , 1 mM L-glutamine, and 2% chicken embryo extract. Additionally, mouse L929 fibroblasts were cultivated (4 ϫ 10 3 cells/well in 96-well microplates) at 37°C in RPMI 1640 medium (pH 7.2 to 7.4) without phenol red (Gibco BRL) supplemented with 10% fetal bovine serum and 2 mM glutamine (RPMI), as reported previously (21) .
In vitro cytotoxicity tests. CCs and L929 cell cultures were incubated at 37°C for different periods of time (24 to 96 h) with increasing concentrations of each compound (up to 96 M) diluted in DMEM (without phenol red). Next, mammalian cell morphology and spontaneous contractibility (of CCs) were evaluated by light microscopy, and cell viability was determined by a colorimetric assay using 10 l alamarBlue (Invitrogen), which was added to each well. After incubation for 24 h, the absorbance at 570 and 600 nm was determined and the results were determined following the manufacturer's instructions. Then, the concentration that reduced cell viability by 50% (LC 50 ) was calculated as reported previously (21) .
Parasites. Bloodstream trypomastigote (BT) forms of the Y and Colombiana strains of T. cruzi were obtained from the blood of infected male Swiss Webster mice at the peak of parasitemia (12) . Immediately after the purification step, the parasites were resuspended in RPMI 1640 medium (pH 7.2 to 7.4) without phenol red (Gibco BRL) supplemented with 10% fetal bovine serum (FBS) and 2 mM glutamine, as reported previously Reagents and conditions were as follows: a, sodium bis(trimethylsilyl)amide; tetrahydrofuran; and 25°C. (18) . The effect against the intracellular forms was investigated through the use of L929 cell lineages infected with tissue culture-derived trypomastigotes (the Tulahuen strain expressing the Escherichia coli ␤-galactosidase gene), using a 10:1 parasite/host cell ratio. The incubation with the tested compounds was performed for 96 h, and previously established protocols were followed (21) . Alternatively, CCs were infected (ratio, 10:1) with bloodstream trypomastigotes (Y strain). After 24 h of interaction, the infected cultures were rinsed and then exposed for 48 h to nontoxic concentrations of the amidines, which had previously been screened on mammalian host cells.
Trypanocidal analysis. The BT forms of the Y and Colombiana strains (5 ϫ 10 6 per ml) were incubated for up to 24 h at 37°C in RPMI in the presence of serial dilutions of the compounds (0 to 32 M), and parasites incubated with culture medium alone were used as controls. After incubation with the compound, the parasite death rates were determined by light microscopy through the direct quantification of the number of live parasites using a Neubauer chamber, and the compound concentration that reduced the number of parasites by 50% (the 50% effective concentration [EC 50 ]) was calculated. Also, the compound concentration that reduced the number of parasites by 90% (EC 90 ) was further calculated in intracellular assays using the Y strain (18) . For the assay with intracellular forms, cardiac cell cultures and cells of the L929 cell line were used as hosts for infection with the Y and Tulahuen strains, respectively. Briefly, Tulahuen-infected L929 cell cultures were exposed to 10 M (corresponding to the EC 90 value of Bz, as reported elsewhere [18] ) each compound diluted in RPMI, and the compounds that resulted in a Ն50% reduction of the parasite infection index were further screened at increased concentrations to determine the EC 50 s (18) . After 96 h of incubation with the compound at 37°C, chlorophenol red glycoside (500 M; Sigma-Aldrich) in 0.5% Nonidet P-40 was added to each well, and the plate was incubated for 18 h at 37°C. Next, the absorbance at 570 nm was measured. Uninfected and T. cruzi-infected cultures exposed to the vehicle and Bz were run in parallel. The results are expressed as the percentage of T. cruzi growth inhibition in compound-tested host cells compared to that in the infected but untreated cells (21) . Triplicate samples were run in the same plate, and at least two assays were performed in each analysis. For the analysis of the effects of the test compounds against intracellular amastigotes of the Y strain, after 24 h of parasite-host cell interaction, the infected CCs were washed to remove free parasites and then incubated for another 48 h with increasing concentrations of the test compounds. CCs were maintained at 37°C in an atmosphere of 5% CO 2 and air, and the medium was replaced every 24 h. Then, the samples were fixed and stained with Giemsa solution (Sigma-Aldrich), and the number of infected host cells and the number of parasites per infected host cell were determined by light microscopy analysis (18) . Only characteristic T. cruzi cells with nuclei and kinetoplasts were counted as surviving parasites, since irregular structures could indicate parasites undergoing death. Compound activity was estimated by calculating the percentage of inhibition upon the infection index (the percentage of infected host cells multiplied by the average number of intracellular amastigotes per infected host cell) (12) . At least two assays were performed in duplicate in each analysis.
LB labeling.
To determine the biogenesis of lipid bodies (LBs) in cardiac cell cultures exposed to amidines, untreated CCs were incubated for 2 to 48 h with the studied compounds at the corresponding EC 50 s (against intracellular forms of the Y strain determined earlier) and then fixed for 10 min with 3.7% formaldehyde in Ca 2ϩ -and Mg 2ϩ -free Hanks balanced salt solution (pH 7.4). Next, the samples were rinsed twice using distilled water, incubated for 5 min in absolute propylene glycol, and stained for 10 min in 0.5% oil red (Sigma-Aldrich). The cultures were incubated for 3 min with 85% propylene glycol and, finally, rinsed twice using distilled water. The samples were incubated or not with 1 g/ml 4,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) for DNA staining (host cells nuclei), rinsed with saline buffer, dried, and mounted using aqueous mounting medium [2.5% 1.4-diazabicyclo-(2.2.2)octane (DABCO)], and the fluorescence was analyzed with a ϫ63 oil objective in a Zeiss photomicroscope (AxioCam) equipped with epifluorescence (Zeiss Inc., Thornwood, NY) and by using a filter set for UV-excited probes. Images were captured using the software AnalySIS OPTI. As positive control, 2 M oleic acid (Sigma-Aldrich) was used to trigger the biogenesis of the lipid bodies (22) .
In vivo acute toxicity. In order to determine the no-observed-adverse-effect level (NOAEL), increasing doses of the tested compounds (up to 200 mg/kg of body weight) were injected by the intraperitoneal (i.p.) route individually in female Swiss Webster mice (weight, 20 to 23 g; n ϭ 2 mice per assay for two assays). Treated animals were inspected for toxic and subtoxic symptoms according to the Organization for Economic Cooperation and Development (OECD) guidelines. At 48 h after compound injection, the NOAEL values were determined as reported previously (23) .
Biochemical analysis. At 48 h after compound administration, mouse blood was collected and immediately submitted to biochemical analysis for determination of the levels of plasma markers, including urea (blood urea nitrogen [BUN]), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatine kinase (CK), which was performed at the animal facilities (CECAL/Fiocruz platform) of the Oswaldo Cruz Foundation (Rio de Janeiro, Brazil) using an Ortho Clinical Vitros 250 chemistry system (Johnson & Johnson), as reported previously (23) .
In vivo infection. Male Swiss Webster mice (weight, 18 to 20 g) obtained from the animal facilities of CECAL were housed at a maximum of 6 per cage, kept in a specific-pathogen-free (SPF) room at 20 to 24°C under a 12-light and 12-h dark cycle, and provided sterilized water and chow ad libitum. The animals were allowed to acclimate for 7 days before starting the experiments. Infection was performed by i.p. injection of 10 4 and 5 ϫ 10 3 bloodstream trypomastigotes (the Y and Colombiana strains, respectively). Age-matched noninfected mice were maintained under identical conditions (12) .
Treatment schemes. AIAs were first dissolved in DMSO and then freshly diluted with sterile distilled water. The stock solution of benznidazole (N-benzyl-2-nitroimidazole acetamide) was prepared in sterile distilled water with 3% Tween 80 (Sigma-Aldrich). The animals were divided into the following groups (5 animals per group): uninfected (noninfected and nontreated), untreated (infected but treated only with vehicle), and treated (infected and treated with the compounds) groups. The therapy (once a day) was performed by the use of different schemes (see Text S2 in the supplemental material). In the first set of assays, T. cruzi (Y strain)-infected mice were treated for only 2 days (at 5 days postinfection [dpi] and at 8 dpi, which correspond to the time of parasitemia onset and the time of peak parasitemia in this experimental model, respectively), using 5 to 20 mg/kg/day AIA (administered i.p.) and 100 mg/kg/day Bz (administered orally). In the second set of experiments, mice were infected with the Colombiana strain and the therapy started at 10 dpi (the time of parasitemia onset in this animal model) were treated for 10 consecutive days with 35DAP073 alone (5 mg/kg/day) or in combination with Bz (0.5 mg/kg/day AIA plus 100 mg/kg/day of Bz). In all assays, only mice with positive parasitemia were used in the infected groups.
Parasitemia and mortality rates. Parasitemia was individually checked by direct microscopic counting of the number of parasites in 5 l of blood, and the mice were checked for mortality daily until 30 days posttreatment. Mortality is expressed as the percent cumulative mortality (CM) as described before (18) .
Determination of blood parasite load by qPCR. For quantitative realtime PCR (qPCR), 500 l blood was diluted in a 1:2 volume of guanidine solution (6 M guanidine-HCl, 0.2 M EDTA; Sigma-Aldrich) and heated for 90 s in boiling water. Blood samples in guanidine-EDTA were processed using a QIAamp DNA minikit (Qiagen) (24) . Quantitative realtime multiplex PCR assays using TaqMan probes targeting T. cruzi satellite nuclear DNA and the internal amplification control (IAC; plasmid pZErO-2 containing an insert from the Arabidopsis thaliana aquaporin gene) were performed as described previously (25) . The standard curves for absolute quantification were constructed with serial dilutions of total DNA ranging from 10 5 parasite equivalents to 0.5 parasite equivalents per ml of blood obtained with a negative blood sample in guanidine-EDTA spiked with 10 5 parasite equivalents per milliliter of blood. Ethics. All procedures were carried out in accordance with the guidelines established by the FIOCRUZ Committee of Ethics for the Use of Animals (CEUA LW16/14).
Statistical analysis. The data represent the means Ϯ standard deviations (SDs) from 2 experiments run in duplicate, and statistical analysis was performed by analysis of variance (ANOVA), with significance being set at a P value of Յ0.05 (23) .
RESULTS
The phenotypic analysis of BT forms (Y strain, discrete typing unit [DTU] II) showed that all studied compounds were active against the parasite. The response to compounds 35DAP073, 35DAP081, 35DAP077, and 35DAP092 was time dependent, with the compounds exhibiting EC 50 s ranging from 0.7 to 28 M and 0.5 to 10 M after 2 and 24 h of incubation, respectively, while the EC 50 of Bz was 13 M after 24 h (Table 1) . Among these four compounds, the most active were 35DAP073 and 35DAP081, and both also displayed the highest selectivity indexes (SIs; 64 and 53, respectively). Statistical analysis revealed that 35DAP073, 35DAP081, and 35DAP092 presented efficacy superior to that of Bz (P Ͻ 0.05). When BT forms of the Colombiana strain (DTU I) were assayed, both amidines showed a trypanocidal effect, with the EC 50 s of 35DAP073 and 35DAP081 being 3.8 Ϯ 2.8 and 1.9 Ϯ 0.4 M, respectively. 35DAP073 and 35DAP081 were very active against intracellular forms of both the Tulahuen (Table 2 ) and Y (Table 3 ) strains of T. cruzi, which are representatives of DTUs VI and II, respectively, and were more potent than Bz (P Յ 0.05). The m-terphenyl bis-AIA 35DAP073 showed higher activity, indicated by the lower EC 90 values (87 nM) after 48 h of incubation, and was about 126-fold more effective than Bz, and it also exhibited the highest SI (SI, 2,000) ( Table 3) .
As 35DAP073 was more effective against intracellular forms than BT forms (Y strain; Tables 1 and 3 ) and the biogenesis of LBs may be induced by different stimuli (26) , the induction of LB biogenesis during incubation of uninfected CCs with this amidine was compared with that during incubation of uninfected CCs with another molecule not active against T. cruzi in vitro (26SMB060). After incubation for different lengths of time (2 to 48 h), our data revealed that both amidines were able to induce LB biogenesis at similar levels very quickly, since strong LB formation compared to that in the untreated group was seen as soon as only 2 h posttreatment, and the profile was similar to that obtained with the positive control (oleic acid) (Fig. 4) . A large number of LBs was also observed after 24 h of amidine exposure, and the levels were maintained up to 48 h, although oleic acid caused the progressive and continuous formation of LB (increases in the number and volume) (Fig. 4) .
Next, due to the high activity and selectivity of 35DAP073 and 35DAP081, Swiss Webster mice were used to determine the NOAEL values of the two compounds. 35DAP073 proved to be less toxic at all doses tested, presenting an NOAEL of 25 mg/kg, while 35DAP081 showed an NOAEL of Ͻ12.5 mg/kg (Table 4) . Plasma biochemical analysis (P Յ 0.1) after 48 h of compound administration did not show any statistically significant differences in the levels of ALT, AST, CK, and BUN among all tested groups (Table 5 ). Due to the findings of these preliminary acute toxicity studies, only 35DAP073 was evaluated in in vivo models of acute T. cruzi infection using nontoxic doses (up to 25 mg/kg/day). In parallel, a control group was orally treated with Bz (100 mg/kg/day) (Fig. 5) .
Our data demonstrated a dose-dependent effect of treatment with 35DAP073 at concentrations of up to 20 mg/kg/day, which led to 96 to 46% reductions in the levels of parasitemia (Fig. 5) . The animal survival rates achieved 100% when the mice were treated with 5 and 10 mg/kg/day of 35DAP073, which was similar to the results obtained with 100 mg/kg/day Bz (Fig. 5) . However, as the tested compound did not result in the complete suppression of the blood parasite load, a longer period of therapy (10 days using 5 mg/kg/day) was next investigated with mice infected with 5 ϫ 10 3 bloodstream trypomastigote forms of the Colombiana strain. Also, 35DAP073 combined with Bz (treatment for 10 days using 0.5 mg/kg/day 35DAP073 and 100 mg/kg/day Bz) was assayed in parallel using the same experimental model described above, with the therapy being started at the time of parasitemia onset. Our findings showed that 5 mg/kg/day of 35DAP073 completely suppressed the parasitemia and gave 100% animal survival, as did Bz (Fig. 6) . However, at the end of the therapy period (the last day of 35DAP073 administration), the mice presented some undesirable neurological toxic disorders (tremors, shaking, ataxia) that were no longer observed after 48 h posttreatment (data not shown). The combination of 0.5 mg/kg/day of this amidine with Bz resulted in parasitemia suppression, 100% animal survival, and no toxic events (Fig. 6) . Analysis by qPCR showed that although no statistically significant difference in blood parasite loads was found among the tested groups (P Ͼ 0.05), monotherapy with Bz and 35DAP073 resulted in mean values of 204 and 265 parasite equivalents (Par. Eq.)/ml, respectively, while the association of Bz with the AIA induced a higher reduction (60%) of the blood parasite load (82 Par. Eq./ml) (Fig. 7 ).
DISCUSSION
The current therapies for Chagas disease remain unsatisfactory due to their various side effects and limited efficacies (27) . Amidines have been used as antiparasitic agents for decades in human and veterinary medicine but show important limitations, such as the need for parenteral administration and undesirable side effects (7) . In order to overcome these limitations, novel amidines have been synthesized and phenotypic analysis of novel amidines has been conducted in vivo and in vitro (12, 28) . Among these, arylimidamides (AIAs) showed considerable biological activity against several intracellular pathogens, including T. cruzi (29) , with the bis-AIAs being the most effective of the group (19) .
A previous study reported the synthesis of dicationic m-terphenyl derivatives and their biological effect against Trypanosoma brucei rhodesiense, Plasmodium falciparum, Leishmania amazonensis, and T. cruzi (16) . Among these, bispyridylimidamides were the most potent against the intracellular amastigote form of the T. cruzi (Tulahuen strain, DTU VI). In the present study, we further explored the phenotypic activity of 14 bis-and monoarylimidamides against BTs and intracellular forms of T. cruzi in vitro and in vivo and extended the analysis to other parasite strains (the Y and Colombiana strains, which belong to DTUs II and I, respectively).
Structural variations of the test compounds used in this study included those in AIA moieties as well as the central cores of the molecules. Maximum potencies were observed with 35DAP073 and 35DAP081, each of which has two 2-pyridylimidamide groups attached to an m-terphenyl nucleus and in which at least one of the two AIA groups is meta to the central ring. These two compounds were more potent than the correspond- ing bisphenylimidamides, 35DAP069 and 35DAP077. The difference in potencies between 35DAP073 and 35DAP069 was greater than 60-fold but was less pronounced than that between 35DAP081 and 35DAP077. The bispyridylimidamides 35DAP073 and 35DAP081 were also more potent than the monopyridylimidamides 35DAP092 and 38DAP096, thus demonstrating the importance of two AIA moieties. Compound 38DAP092, in which the AIA group is meta to the central ring, was more potent than its regioisomer, 38DAP096, which bears a para-AIA moiety. None of the bis-AIAs with lone aromatic rings or aliphatic chains between the two AIA functionalities ( Fig. 2 and  3) showed detectable activity.
The most active molecule, the m-terphenyl bis-AIA 35DAP073, showed an EC 50 of 0.5 M against trypomastigotes (Y strain) after 24 h and was more effective than the reference drug, Bz (13 M). This amidine was also active against a highly naturally resistant strain (Colombiana), exhibiting an EC 50 of 3.8 M. Analysis of its activity against intracellular forms (Tulahuen strain) showed that this bis-AIA (EC 50 ϭ 0.04 M) was about 50-fold more active than Bz (2 M). The greater effect against intracellular forms than BT forms was dissociated from the ability of the amidines to induce LB accumulation within mammalian host cells. The biogenesis of lipid bodies is a central event in several processes of cellular homeostasis, as well as during intracellular pathogen infection (30, 31) . LBs are recognized to be dynamic organelles composed of a triglyceride and cholesteryl ester core with a surrounding monolayer of phospholipid, cholesterol, and a variety of associated proteins with diverse functions in cell metabolism, signaling, and inflammation (14, 32) . Under inflammatory and infectious conditions, prostaglandins and other lipid mediators are mainly produced by LBs (33) . Also, recent findings showed that antimicrobial compounds may induce an accumulation of lipid droplets in the cytoplasm of Candida spp. (34) and protozoans (35) . In Mycobacterium leprae-infected cells, LBs showed a strong ability to fuse, forming giant lipid droplets (36) . Since amidines can modulate the functional activities of mammalian host cells linked to the control of parasite proliferation and/or survival (37, 38) and LBs act on cellular metabolism, inflammation, and infectious conditions (14, 32) , in the present study we investigated whether the studied AIAs could interfere with LB biogenesis and parasitism control in vitro. Our data also demonstrated that 35DAP073 and 28SMB060 were able to induce LB biogenesis in cardiac cells at all times tested (2 to 48 h), with cells treated with the two compounds exhibiting similar morphological profiles. No correlation between the trypanocidal effect of amidines and LB accumulation in CCs was found, but further studies are desirable to better understand the consequences of the higher LB levels induced by the amidines in the parasite as well the consequences on the mammalian cell physiology, since this modulation may influence the growth of intracellular parasites (36) .
Next, due to the excellent selective indexes of 35DAP073 and 35DAP081, both were tested for acute toxicity. The results showed NOAEL values of 25 and 12.5 mg/kg for 35DAP073 and 35DAP081, respectively. Then, in vivo efficacy studies were conducted with 35DAP073 at concentrations of Ͻ25 mg/kg. Our data demonstrated that 35DAP073 treatment of mice infected with the Y and Colombiana strains resulted in a dose-dependent action of 35DAP073, leading to 96 to 46% reductions of parasitemia and 100% animal survival, with Bz showing a similar effect. Unfortunately, as the 10 daily doses (at 5 mg/kg i.p.) were toxic for the animals, combined therapy with 35DAP073 and Bz was tested with the aim of reducing the toxic effects of the amidine. Monotherapy with 35DAP073 at only 0.5 mg/kg/day was not attempted, as previous data with related amidines demonstrated that doses of Յ5 mg/kg/day had only a mild effect on parasitemia control (23) . As was also found by our group (28) using the combination of Bz with the amidine DB289, the association of 0.5 mg/kg 35DAP073 with Bz in the present study improved the control of parasite proliferation, providing a 9-fold enhancement of activity compared to that of Bz alone. qPCR analysis showed that the combination therapy was the best regimen, exhibiting parasitemia suppression with no detectable toxicity to the animals. In this sense, our results support further experimental investigations of this compound class in association with licensed antiparasitic drugs with the aim of contributing to the identification of novel alternatives for the treatment of neglected parasitic diseases, such as Chagas disease.
